Kalytera to Present New Data that Supports the Continued Investigation of KAL671 for the Treatment of Osteoporosis in Prader-Willi Syndrome at the IPWSO Conference

Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, is scheduled to present at the International Prader-Willi Syndrome Organization (“IPWSO”) Conference on Friday, July 22, 2016. The event is being held at the Sheraton...
Continue Reading